Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Research works printed but not linked: 1
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Items 201–300 of 589
Organoid-on-a-chip: Current challenges, trends, and future scope toward medicine
Li, Z., Li, Q., Zhou, C., Lu, K., Liu, Y., Xuan, L., & Wang, X. (2023) · Biomicrofluidics · doi:10.1063/5.0171350 · Cited by 36
Self-citationMa, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 40
Wu, Y., Zhou, Y., Qin, X., & Liu, Y. (2021) · Biomicrofluidics · doi:10.1063/5.0062697 · Cited by 38
Organ-on-Chip platforms to study tumor evolution and chemosensitivity
Dsouza, V. L., Kuthethur, R., Kabekkodu, S. P., & Chakrabarty, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188717 · Cited by 39
Liu, C., Li, K., Sui, X., Zhao, T., Zhang, T., Chen, Z., Wu, H., Li, C. R., Li, H., Yang, F., et al. (2024) · Advanced Science · doi:10.1002/advs.202400185 · Cited by 48
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Williams, S. T., Wells, G., Conroy, S., Gagg, H., Allen, R. J., Rominiyi, O., Helleday, T., Hullock, K., Pennington, C. E. W., Rantala, J., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.32 · Cited by 37
Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions
Visalakshan, R. M., Lowrey, M. K., Sousa, M. G. C., Helms, H. R., Samiea, A., Schutt, C. E., Moreau, J. M., & Bertassoni, L. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162905 · Cited by 35
Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0071 · Cited by 36
Self-citationAdvances in Modeling the Immune Microenvironment of Colorectal Cancer
Yoon, P., Piccolo, N. D., Shirure, V. S., Peng, Y., Kirane, A., Canter, R. J., Fields, R. C., George, S. C., & Gholami, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614300 · Cited by 35
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 35
Xue, G., Li, X., Kalim, M., Fang, J., Jiang, Z., Zheng, N., Wang, Z., Li, X., Abdelrahim, M., He, Z., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.001 · Cited by 32
Song, F., Wang, C., Wang, T., Tao, Y.-C., Mao, J., Hu, C.-W., Zhang, Y. X., Tang, P., Lu, C., Qing, H.-L., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155944 · Cited by 30
Monitoring Cancer Cell Invasion and T-Cell Cytotoxicity in 3D Culture
Lin, Y.-N., Nasir, A., Camacho, S., Berry, D. L., Schmidt, M. O., Pearson, G. W., Riegel, A. T., & Wellstein, A. (2020) · Journal of Visualized Experiments · doi:10.3791/61392 · Cited by 39
Seliger, B., & Ferrone, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_15 · Cited by 32
Weydert, Z., Lal‐Nag, M., Mathews-Greiner, L., Thiel, C., Cordes, H., Kuepfer, L., Guye, P., Kelm, J. M., & Ferrer, M. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219880194 · Cited by 32
Key aspects for conception and construction of co-culture models of tumor-stroma interactions
Mason, J. E., & Öhlund, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1150764 · Cited by 32
“In this case, these models were used to examine immune checkpoint blockade, identifying that TBK1/IKKε inhibition enhanced response to programmed cell death protein 1 blockade and matched tumor response in vivo (Jenkins et al., 2018).”
MethodProtocol for ex vivo culture of patient-derived tumor fragments
Roelofsen, L. M., Voabil, P., de Bruijn, M. J. W., Herzig, P., Zippelius, A., Schumacher, T. N., & Thommen, D. S. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102282 · Cited by 36
Incorporating Immune Cells into Organoid Models: Essential for Studying Human Disease
Bogoslowski, A., An, M., & Penninger, J. M. (2023) · Organoids · doi:10.3390/organoids2030011 · Cited by 34
“In contrast, tumor organoids can recapitulate features of the primary tissues both genetically and histologically and can even mimic responses to therapy [84].”
BackgroundEngineered models of tumor metastasis with immune cell contributions
Graney, P. L., Tavakol, D. N., Chramiec, A. G., Ronaldson-Bouchard, K., & Vunjak‐Novakovic, G. (2021) · iScience · doi:10.1016/j.isci.2021.102179 · Cited by 33
Biomedical Applications of Non-Small Cell Lung Cancer Spheroids
Rozenberg, J. M., Filkov, G. I., Trofimenko, A. V., Karpulevich, E., Parshin, V. D., Royuk, V. V., Sekacheva, M. I., & Durymanov, M. O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.791069 · Cited by 32
“These studies revealed a marked increase in pro-inflammatory cytokine expression and CD8+ T-cell fraction (37, 87).”
BackgroundImmuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy
Shelkey, E., Oommen, D., Stirling, E. R., Soto‐Pantoja, D. R., Cook, K. L., Lu, Y., Votanopoulos, K. I., & Söker, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13930-7 · Cited by 31
Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays
Wang, X., Scarfò, I., Schmidts, A., Toner, M., Maus, M. V., & Irimia, D. (2019) · Advanced Science · doi:10.1002/advs.201901829 · Cited by 29
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 32
“Using a microfluidic chip, Jenkins et al ., were able to evaluate the response and resistance to PD-1 blockade, by profiling the secreted cytokines in multi-cellular PDOs [95].”
MethodLugand, L., Mestrallet, G., Laboureur, R., Dumont, C., Bouhidel, F. A., Djouadou, M., Masson-Lecomte, A., Desgrandchamps, F., Culine, S., Carosella, E. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898732 · Cited by 33
Galectins in the Tumor Microenvironment: Focus on Galectin-1
Martínez‐Bosch, N., & Navarro, P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_2 · Cited by 31
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
Organotypic Models for Functional Drug Testing of Human Cancers
Huang, Y. L., Dickerson, L. K., Kenerson, H. L., Jiang, X., Pillarisetty, V. G., Tian, Q., Hood, L., Gujral, T. S., & Yeung, R. S. W. (2023) · BME Frontiers · doi:10.34133/bmef.0022 · Cited by 29
Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming
Barry-Hundeyin, M., Kurz, E., Mishra, A., Rossi, J. A. K., Liudahl, S. M., Leis, K. R., Mehrotra, H., Kim, M., Torres, L. E., Ogunsakin, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0161 · Cited by 31
Self-citation3D cell culture models in research: applications to lung cancer pharmacology
Vella, N., Fenech, A. G., & Magri, V. P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438067 · Cited by 36
Yao, N., Jing, N., Lin, J., Niu, W., Yan, W., Yuan, H., Xiong, Z., Hou, Q., Qiao, X., Liu, Q., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01523-w · Cited by 33
“Notably, MDOTS/ PDOTS from immunocompetent murine models or human tumor samples can be established and assessed for 7–14 days [21, 23, 36].”
Barbie, D. A., Spira, A. I., Kelly, K. L., Humeniuk, R., Kawashima, J., Kong, S., & Koczywas, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.07.004 · Cited by 26
Self-citationDeng, J., Thennavan, A., Shah, S. M., Bagdatlioglu, E., Klar, N. J., Heguy, A., Marier, C., Meyn, P., Zhang, Y., Labbe, K. E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05936-4 · Cited by 27
Self-citationLung Cancer Organoids: The Rough Path to Personalized Medicine
Rossi, R., Angelis, M. L. D., Xhelili, E., Sette, G., Eramo, A., Maria, R. D., Incani, U. C., Francescangeli, F., & Zeuner, A. (2022) · Cancers · doi:10.3390/cancers14153703 · Cited by 31
Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies
Ngo, T. K. N., Kuo, C., & Tu, T. (2023) · Biomicrofluidics · doi:10.1063/5.0108792 · Cited by 27
In Vitro Three-Dimensional (3D) Models for Melanoma Immunotherapy
Nomdedeu‐Sancho, G., Gorkun, A. A., Mahajan, N., Willson, K., Schaaf, C. R., Votanopoulos, K. I., Atala, A., & Söker, S. (2023) · Cancers · doi:10.3390/cancers15245779 · Cited by 30
Zhao, Z., Zhang, S., Jiang, N., Zhu, W., Song, D., Liu, S., Yu, W., Bai, Y., Zhang, Y., Wang, X., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202317613 · Cited by 29
Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine
Kaur, G., Evans, D. M., Teicher, B. A., & Coussens, N. P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211038362 · Cited by 25
Krysko, D. V., Demuynck, R., Efimova, I., Naessens, F., Krysko, O., & Catanzaro, E. (2022) · Cells · doi:10.3390/cells11223705 · Cited by 27
Use and application of organ-on-a-chip platforms in cancer research
Yu, Y., Zhou, T., & Cao, L.-L. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00790-7 · Cited by 31
“…organotypic tumor spheroids and PDOTSs composed of autologous lymphocytes and myeloid cells were co-cultured on a chip for the analysis of in vitro ICB therapy for breast cancer (Jenkins et al. 2018); this ex vivo platform was found to retain key tumor-infiltrating T-lymphocyte populations.”
MethodOrganoids: new frontiers in tumor immune microenvironment research
Yang, Y., Cui, J., Kong, Y., Hou, Y., & Ma, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422031 · Cited by 32
Calpe, B., & Kovacs, W. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1756769 · Cited by 30
“not yet HTS-compatible, it illustrates the potential of MTS for drug discovery in immuno-oncology [138].”
BackgroundPDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
“A study led by Jenkins demonstrated the use of an organotypic 3D microfluidic culture from murine and patient derived tumor tissue, which retained the native immune TME, in assessing response and resistance to immune checkpoint blockade (Jenkins et al., 2018).”
BackgroundEngineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies
Campisi, M., Shelton, S. E., Chen, M., Kamm, R. D., Barbie, D. A., & Knelson, E. H. (2022) · Cancers · doi:10.3390/cancers14153561 · Cited by 25
“Since MPS require few cells, microfluidic culture can conserve immune cells, as seen in applications with patient-derived organotypic tumor spheroids (PDOTS) and murine MDOTS [33].”
BackgroundSelf-citationKim, Y., Ko, J., Shin, N., Park, S., Lee, B., Kim, S., Song, J., Lee, S.-J., Kang, K., Lee, J., et al. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28221 · Cited by 26
Khayamian, M. A., Abadijoo, H., Shalileh, S., Ghaderinia, M., Simaee, H., Abbasvandi, F., Esmailinejad, M. R., Sanati, H., Ghafari, H., Parizi, M. S., et al. (2023) · Nano Energy · doi:10.1016/j.nanoen.2023.108510 · Cited by 24
Landon‐Brace, N., Li, N. T., & McGuigan, A. P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300903 · Cited by 28
Poggi, A. D., Villa, F., Fernandez, J. L. C., Costa, D., Zocchi, M. R., & Benelli, R. (2021) · Cancers · doi:10.3390/cancers13143417 · Cited by 27
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids
Hill, S. J., & D’Andrea, A. D. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0527 · Cited by 23
Mary, G., Malgras, B., Perez, J. E., Nagle, I., Luciani, N., Pimpie, C., Asnacios, A., Pocard, M. D., Reffay, M., & Wilhelm, C. (2022) · Cancers · doi:10.3390/cancers14020366 · Cited by 28
Wu, Z., Ao, Z., Cai, H., Li, X., Chen, B., Tu, H., Wang, Y., Lu, R. O., Gu, M., Cheng, L., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01786-6 · Cited by 25
Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges
Basnayake, B. W. M. T. J., Leo, P., Rao, S., Vasani, S. S., Kenny, L., Haass, N. K., & Punyadeera, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02167-4 · Cited by 28
“Complex cancer organoid models have been developed to overcome these limitations by co-culturing cancer organoids with immune cells [112], cancer-associated fibroblasts [113], and mesodermal progenitor cells [111, 114, 115].”
BackgroundEmerging roles of TBK1 in cancer immunobiology
Miranda, A., Shirley, C. A., & Jenkins, R. W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.007 · Cited by 39
Self-citationTucker, E. R., George, S. L., Angelini, P., Bruna, A., & Chesler, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040248 · Cited by 25
“This unique experimental platform has already been used to evaluate the response of murine and patient-derived 3D tumour cultures to immune checkpoint blockade [101].”
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167651 · Cited by 21
“In addition, to investigate whether high MYC levels might be useful for prospectively predicting sensitivity to combined KRAS G12C/eIF4A inhibitors, human KRAS G12C–mutant NSCLC explants expressing either high levels of MYC (DFCI-730, DFCI-456, MGH-9029-1B) or low levels of MYC (MGH-1112-1, MGH-1196-2) were used to ge…”
InfluentialSelf-citationN-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma
Miranda, A., Pattnaik, S., Hamilton, P. T., Fuss, M. A., Kalaria, S., Laumont, C. M., Smazynski, J., Mesa, M., Banville, A. C., Jiang, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj5428 · Cited by 22
“To address this, we are pursuing a patient-derived organotypic tumor spheroid approach, which allows modeling of the native tumor immune microenvironment in primary human tumor samples ( 49 ).”
MethodSelf-citationPatient-derived Organoids in Bladder Cancer: Opportunities and Challenges
Radić, M., Egger, M., Julio, M. K., & Seiler, R. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.08.008 · Cited by 22
Microdissection tools to generate organoids for modeling the tumor immune microenvironment
Cordts, S. C., Yuki, K., Echeverri, M. F. H., Narasimhan, B., Kuo, C. J., & Tang, S. K. Y. (2024) · Microsystems & Nanoengineering · doi:10.1038/s41378-024-00756-8 · Cited by 22
“This prior study revealed that spheroids > 100 μ m, 40 – 100 μ m, and 40 μ m cultured in a 3D micro fl uidic device displayed insigni fi cant differences in live immune populations 28 .”
Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation
Trotta, R., Rivis, S., Zhao, S., Orban, M., Cafarello, S. T., Charatsidou, I., Poźniak, J., Dehairs, J., Vanheer, L., Pulido-Vicuña, C. A., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0415 · Cited by 24
Immune organoid for cancer immunotherapy
Wang, X., Wang, W., & Sun, Z. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.031 · Cited by 27
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Affolter, A., Kern, J., Bieback, K., Scherl, C., Rotter, N., & Lammert, A. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5378 · Cited by 23
“The response of murine‐ and patient‐derived organotypic tumor spheroids from various entities to immune checkpoint blockade was assessed using a 3D microfluidic device (118).”
MethodTargeting alternative splicing in cancer immunotherapy
Han, N., & Liu, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232146 · Cited by 22
“, 2019), ICB therapy (Jenkins et al., 2018), or other neoantigen-based immunotherapies (Courau et al.”
BackgroundLapidot, M., Case, A. E., Larios, D., Gandler, H. I., Meng, C., Tošić, I., Weisberg, E., Poitras, M. J., Gokhale, P. C., Paweletz, C. P., et al. (2020) · Cancers · doi:10.3390/cancers13010007 · Cited by 21
“MPM tumor specimens, MSTO-211H or LP9 cells were used to prepare MPM spheroids analogous to previous preparations [40] In brief, fresh MPM tumor specimens were minced in Dulbecco’s Modified Eagle’s medium (DMEM) (containing 10% FBS, 100 mmol/L Na pyruvate, Corning CellGro, Tewksbury, MA, USA), 100 U/mL collagenase typ…”
MethodSelf-citationMinkler, S. J., Lucien, F., Kimber, M. J., Sahoo, D. K., Bourgois‐Mochel, A., Musser, M. L., Johannes, C. M., Frank, I., Cheville, J. C., Allenspach, K., et al. (2021) · Cancers · doi:10.3390/cancers13030422 · Cited by 21
Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine
Boehnke, N., & Hammond, P. T. (2021) · JACS Au · doi:10.1021/jacsau.1c00313 · Cited by 22
Chen, D., Xu, L., Xuan, M., Chu, Q., & Xue, C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1802 · Cited by 25
“Especially, organotypic tumour spheroids derived from patients contain the cancer cells and autologous immune/stromal cells 76,77 and represent a candidate system mimicking the actual TME.”
BackgroundDesign of a potent interleukin-21 mimic for cancer immunotherapy
Chun, J.-H., Lim, B. S., Roy, S., Walsh, M. J., Abhiraman, G. C., Zhangxu, K., Atajanova, T., Revach, O., Clark, E. C., Li, P., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adx1582 · Cited by 23
Self-citationBarneh, F., Mirzaie, M., Nickchi, P., Tan, T. Z., Thiery, J. P., Piran, M., Salimi, M., Goshadrou, F., Aref, A. R., & Jafari, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby030 · Cited by 19
Self-citationTargeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Breast cancer organoids and their applications for precision cancer immunotherapy
Guan, D., Liu, X., Shi, Q., He, B., Zheng, C., & Meng, X. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03231-2 · Cited by 23
“Cultivation and assessment of MDOTS/PDOTS from syngeneic immunoreactive murine models and tumor samples of patients are achieved for 1–2 weeks, such as Merkel cell carcinoma and melanoma [56, 57].”
MethodBiomarkers and experimental models for cancer immunology investigation
Xu, H., Jia, Z., Liu, F., Li, J., Huang, Y., Jiang, Y., Pu, P., Shang, T., Tang, P., Zhou, Y., et al. (2023) · MedComm · doi:10.1002/mco2.437 · Cited by 24
“Thus, validation of the efficacies of immunotherapy 241,243,259 and testing of novel immunotherapies 28,244 can be carried out.”
BackgroundMethodInfluentialSelf-citationBonnet, V., Maikranz, E., Madec, M., Vertti‐Quintero, N., Cuche, C., Mastrogiovanni, M., Alcover, A., Bartolo, V. D., & Baroud, C. N. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316500121 · Cited by 22
Dominijanni, A. J., Mazzocchi, A. R., Shelkey, E., Forsythe, S. D., Devarasetty, M., & Söker, S. (2020) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2020.03.005 · Cited by 20
Zhang, Z., Liu, L., Ma, C., Cui, X., Lam, R. H. W., & Chen, W. (2021) · Small Methods · doi:10.1002/smtd.202100197 · Cited by 21
Alam, M., Ansari, M. M., Noor, S., Mohammad, T., Hasan, G. M., Kazim, S. N., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.157 · Cited by 22
Advancements in melanoma cancer metastasis models
Melo, L. M. N., Kumar, S., Riess, V., Szylo, K. J., Eisenburger, R. T., Schadendorf, D., Ubellacker, J. M., & Tasdogan, A. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13078 · Cited by 24
“…In vitro 2D cell culture, 3D tumor organoids, ex vivo tumor explant, and B16F10 Melanoma Mouse Model Iwai et al. (2002), Iwai et al. (2005), Jenkins et al. (2018), Pfannenstiel et al. (2019), Powley et al. (2020), Yang et al. (2008) Anti- CTLA- 4 antibody, GM- CSF vaccine, and combinatory…”
MethodBozym, D. J., Zheng, D. X., Revach, O., Aref, A. R., & Jenkins, R. W. (2025) · Lab on a Chip · doi:10.1039/d5lc00062a · Cited by 21
Self-citationEngineering Heterogeneous Tumor Models for Biomedical Applications
Wu, Z., Huang, D., Wang, J., Zhao, Y., Sun, W., & Shen, X. (2023) · Advanced Science · doi:10.1002/advs.202304160 · Cited by 25
Establishing mouse and human oral esophageal organoids to investigate the tumor immune response
Jiang, Y., Zhao, H., Kong, S., Zhou, D., Dong, J., Cheng, Y., Zhang, S., Wang, F., Kalra, A., Yang, N., et al. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050319 · Cited by 20
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
Revach, O., Cicerchia, A. M., Shorer, O., Palin, C. A., Petrova, B., Anderson, S., Liu, B., Park, J. C., Chen, L., Mehta, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102210 · Cited by 30
“15 PDOTS derived from patients with advanced melanoma ( n = 27) were treated with anti-PD-1 (pembrolizumab) ± anti-CD38 (daratumumab), compared to untreated controls (Figure 6A and Table S10).”
InfluentialSelf-citationTBK1 as a regulator of autoimmunity and antitumor immunity
Shi, J., Xie, X., & Sun, S. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.165 · Cited by 19
Multimodal predictors for precision immunotherapy
Roelofsen, L. M., Kaptein, P., & Thommen, D. S. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100071 · Cited by 20
“1 have been found to result in increased PD-L1 expression in several cancer types, such as Hodgkin’s lymphoma, mediastinal large B-cell lymphoma, and in both non-small-cell lung cancer (NSCLC) and small-cell lung cancer.12 Importantly, Hodgkin’s lymphomas, which harbor PD-L1 locus alterations in up to 97%, show partic…”
MethodInfluentialTBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent Vulnerability
Bakouny, Z., & Barbie, D. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1525 · Cited by 16
Self-citationEngineering the Immune Microenvironment into Organoid Models
Luckett, K. A., & Ganesh, K. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040659 · Cited by 23
Chan, W. S., Mo, X.-T., Ip, P. P. C., & Tse, K. Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6521 · Cited by 23
“61,63,64 Microfluidic chambers contain inter-connected multi-and microchannels.”
Semiconducting polymer dots for multifunctional integrated nanomedicine carriers
Zhang, Z., Yu, C., Wu, Y., Wang, Z., Xu, H., Yan, Y., Zhan, Z., & Yin, S. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101028 · Cited by 25
Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold
Hu, L., Yang, X. F., Lan, H., Fang, X., Chen, X., & Jin, K. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112858 · Cited by 22
Reconstruction of tumor microenvironment via in vitro three-dimensional models
Zhou, Z., He, J., Pang, Y., & Sun, W. Y. (2023) · Biofabrication · doi:10.1088/1758-5090/acd1b8 · Cited by 18
“Jenkins et al [121] profiled PD-1 blockade in brain tumor organoids embedded in the 3D collagen hydrogel using a microfluidic device.”
Organoids as Tools for Investigating Skin Aging: Mechanisms, Applications, and Insights
Wang, X., Jia, Q., Li, J., & Zheng, H.-Y. (2024) · Biomolecules · doi:10.3390/biom14111436 · Cited by 19
“Further, this melanoma organoid was used for evaluating drug effectiveness on melanoma [51].”
Advanced Biomanufacturing Technologies for Micro-physiological Systems
Kim, M. K., Yoon, J., Kim, D., Kim, J., Kim, J.-S., Go, G., Song, J., Son, S., Park, K., Lee, J., et al. (2025) · International Journal of Precision Engineering and Manufacturing · doi:10.1007/s12541-025-01330-6 · Cited by 16
Self-citationPatient-derived models: Advanced tools for precision medicine in neuroblastoma
Aaltonen, K. E., Radke, K., Adamska, A., Seger, A., Mañas, A., & Bexell, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1085270 · Cited by 21
Microphysiological Systems for Cancer Immunotherapy Research and Development
Peng, Y., & Lee, E. (2023) · Advanced Biology · doi:10.1002/adbi.202300077 · Cited by 17
Sun, Y., Maggs, L., Panda, A., Wright, S. J., Cicerchia, A. M., Jenney, A., Perricone, M. D., Mills, C. E., Cattaneo, G., Ventin, M., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1011 · Cited by 21
Self-citationMaggs, L., & Ferrone, S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0358 · Cited by 20
Organotypic Modeling of the Tumor Landscape
Haykal, M. M., Nahmias, C., Varon, C., & Martin, O. C. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606039 · Cited by 20
Ninno, A. D., Bertani, F. R., Gerardino, A., Schiavoni, G., Musella, M., Galassi, C., Mattei, F., Sistigu, A., & Businaro, L. (2021) · Journal of Visualized Experiments · doi:10.3791/61895 · Cited by 20
Organoid Models for Cancer Research—From Bed to Bench Side and Back
Kastner, C., Hendricks, A., Deinlein, H., Hankir, M. K., Germer, C., Schmidt, S., & Wiegering, A. (2021) · Cancers · doi:10.3390/cancers13194812 · Cited by 18
Evolution of precision oncology‐guided treatment paradigms
DasGupta, R., Yap, A., Yong, E. Y., & Chia, S. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1585 · Cited by 21
Song, S., Tang, H., Ran, T., Fěng, F., Tong, L., Chen, H., Xie, H., & Lu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115034 · Cited by 18
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.